Premenstrual dysphoric disorder

Premenstrual Syndrome and Premenstrual Dysphoric Disorder
UNC School of Medicine
https://www.med.unc.edu

Premenstrual Dysphoric disorder
http://psychopathology.wiki.westga.edu/

Premenstrual Disorders  - Premenstrual Syndrome / Premenstrual Dysphoric Disorders
Folake V Falaki
http://www.fpm.emory.edu/

Sexuality: Choices in Sexual Behavior
Michael Hall
http://www.cabrillo.edu

Basic Physiology and Neurochemistry of Three Psychiatric Diseases, Including Drug Dependence
Carlton Erickson, Ph.D.
http://www.utexas.edu/

Gender and Mood
David Printz, MD
http://www.columbia.edu

Mood Disorders
http://www.mccc.edu

Major Depressive Disorder
http://people.usd.edu

Mood Disorders Bipolar Disorders Depressive Disorders
http://campus.houghton.edu

Diagnosis and Management of Mood Disorders in Women in a Primary Care Setting
Katherine C. Smith, D.O.
http://www.vcu.edu

Psychopharmacology in Psychiatry
Heidi Combs, MD, Shamim Nejad, MD
http://depts.washington.edu

Female Sexual Anatomy
http://intranet.dwci.edu

Clinical Assessment and Diagnosis - Assessing Psychological Disorders
http://www.abac.edu

Sex and Your Body - Female Sex Organs
http://websites.rcc.edu

323 Published articles on Premenstrual dysphoric disorder

1. Elevated gray matter volume of the emotional cerebellum in women with premenstrual dysphoric disorder.
2. The effect of premenstrual dysphoric disorder and menstrual cycle phase on brain activity during response inhibition.
3. Menstrual cycle effects on amygdala reactivity to emotional stimulation in premenstrual dysphoric disorder.
4. Biopsychosocial aspects of premenstrual syndrome and premenstrual dysphoric disorder.
5. Premenstrual dysphoric disorder: evidence for a new category for DSM-5.
6. [Premenstrual Dysphoric Disorder (PMDD) as an independent disease].
7. Premenstrual dysphoric disorder as a correlate of suicidal ideation, plans, and attempts among a nationally representative sample.
8. Nocturnal polysomnographic sleep across the menstrual cycle in premenstrual dysphoric disorder.
9. When should surgical treatment be considered for premenstrual dysphoric disorder?
10. Pathophysiology of premenstrual syndrome and premenstrual dysphoric disorder.
11. Rapid response to fluoxetine in women with premenstrual dysphoric disorder.
12. Prevalence, correlates, comorbidities, and suicidal tendencies of premenstrual dysphoric disorder in a nationwide sample of Korean women.
13. Premenstrual dysphoric disorder: evidence for a new category for DSM-5.
14. Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis.
15. Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets.
16. Gray matter abnormalities in patients with premenstrual dysphoric disorder: an optimized voxel-based morphometry.
17. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample in China.
18. Elevated serum cholesterol levels in women with premenstrual dysphoric disorder.
19. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome.
20. A comparison of the prevalence of premenstrual dysphoric disorder and comorbidities among adolescents in the United States of America and Nigeria.
21. Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder.
22. Myo-inositol in the treatment of premenstrual dysphoric disorder.
23. Premenstrual syndrome and premenstrual dysphoric disorder.
24. The burden of moderate/severe premenstrual syndrome and premenstrual dysphoric disorder in a cohort of Latin American women.
25. Working memory deficit in premenstrual dysphoric disorder and its associations with difficulty in concentrating and irritability.
26. Posttraumatic stress disorder and trauma characteristics are correlates of premenstrual dysphoric disorder.
27. Attitudes of Spanish women toward premenstrual symptoms, premenstrual syndrome and premenstrual dysphoric disorder: results of a nationwide survey.
28. Premenstrual dysphoric disorder in women with epilepsy: relationships to potential epileptic, antiepileptic drug, and reproductive endocrine factors.
29. Reduced phase-advance of plasma melatonin after bright morning light in the luteal, but not follicular, menstrual cycle phase in premenstrual dysphoric disorder: an extended study.
30. Lifetime discrimination associated with greater likelihood of premenstrual dysphoric disorder.
31. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
32. Fulfillment of the premenstrual dysphoric disorder criteria confirmed using a self-rating questionnaire among Japanese women with depressive disorders.
33. Prevalence of violence exposure in women with premenstrual dysphoric disorder in comparison with other gynecological patients and asymptomatic controls.
34. Patients with premenstrual dysphoric disorder have increased startle modulation during anticipation in the late luteal phase period in comparison to control subjects.
35. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice].
36. Premenstrual dysphoric disorder: prevalence and effects on nursing students' academic performance and clinical training in Kuwait.
37. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder.
38. Diagnosing premenstrual dysphoric disorder: the reliability of a structured clinical interview.
39. The Premenstrual Symptoms Screening Tool revised for adolescents (PSST-A): prevalence of severe PMS and premenstrual dysphoric disorder in adolescents.
40. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a representative cohort of Spanish women of fertile age.
41. Neuroimaging evidence of cerebellar involvement in premenstrual dysphoric disorder.
42. The complexity of premenstrual dysphoric disorder--risk factors in the population of Polish women.
43. Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder.
44. Exposure to American culture is associated with premenstrual dysphoric disorder among ethnic minority women.
45. [Diagnostic and therapeutic algorithm for the treatment of premenstrual dysphoric disorder].
46. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese high school students.
47. Increased sensitivity to light-induced melatonin suppression in premenstrual dysphoric disorder.
48. Premenstrual dysphoric disorder among medical students of a Nigerian university.
49. Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics.
50. The impact of premenstrual dysphoric disorder among 92 bipolar patients.
51. Analysis of the serotonin transporter promoter rs25531 polymorphism in premenstrual dysphoric disorder.
52. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample.
53. Neuroticism-related personality traits are related to symptom severity in patients with premenstrual dysphoric disorder and to the serotonin transporter gene-linked polymorphism 5-HTTPLPR.
54. Premenstrual dysphoric disorder--review of actual findings about mental disorders related to menstrual cycle and possibilities of their therapy.
55. The high-sweet-fat food craving among women with premenstrual dysphoric disorder: emotional response, implicit attitude and rewards sensitivity.
56. Premenstrual dysphoric disorder: neuroendocrine interferences.
57. Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder.
58. Sleep, Hormones, and Circadian Rhythms throughout the Menstrual Cycle in Healthy Women and Women with Premenstrual Dysphoric Disorder.
59. Histories of major depression and premenstrual dysphoric disorder: Evidence for phenotypic differences.
60. Premenstrual dysphoric disorder: out of the appendix.
61. Timing of alcohol use and the incidence of premenstrual syndrome and probable premenstrual dysphoric disorder.
62. Understanding and treating premenstrual dysphoric disorder: an update for the women's health practitioner.
63. Treating premenstrual dysphoric disorder. Options include drugs targeting serotonin and various types of hormone therapy.
64. [The medicalization of feminine suffering: premenstrual dysphoric disorder].
65. Antidepressant prescribing by specialty and treatment of premenstrual dysphoric disorder.
66. Repetitive transcranial magnetic stimulation for premenstrual dysphoric disorder: a case report.
67. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness.
68. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder.
69. Update on research and treatment of premenstrual dysphoric disorder.
70. Acupuncture for premenstrual dysphoric disorder.
71. Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls.
72. Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial.
73. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review.
74. An animal model of premenstrual dysphoric disorder sensitive to antidepressants.
75. Herbals Medicine Also Effective in Treatment of Premenstrual Dysphoric Disorder (PMDD)?
76. Premenstrual dysphoric disorder (PMDD).
77. YAZ in the treatment of premenstrual dysphoric disorder.
78. Premenstrual syndrome and premenstrual dysphoric disorder in adolescents.
79. Late, but not early, wake therapy reduces morning plasma melatonin: relationship to mood in Premenstrual Dysphoric Disorder.
80. Premenstrual dysphoric disorder: burden of illness and treatment update.
81. Management strategies for premenstrual syndrome/premenstrual dysphoric disorder.
82. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women.
83. Levetiracetam for treatment of premenstrual dysphoric disorder: a pilot, open-label study.
84. Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol.
85. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.
86. Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder).
87. The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women.
88. The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment.
89. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder.
90. Duloxetine for premenstrual dysphoric disorder: a pilot study.
91. Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols.
92. Premenstrual dysphoric disorder amongst Nigerian university students: prevalence, comorbid conditions, and correlates.
93. Burden of premenstrual dysphoric disorder on health-related quality of life.
94. The pharmacologic management of premenstrual dysphoric disorder.
95. Lower insulin-like growth factor-1 concentrations in women with premenstrual dysphoric disorder.
96. Altered autonomic nervous system activity as a potential etiological factor of premenstrual syndrome and premenstrual dysphoric disorder.
97. Proton magnetic resonance spectroscopy measurement of brain glutamate levels in premenstrual dysphoric disorder.
98. Toward a functional neuroanatomy of premenstrual dysphoric disorder.
99. Effective treatment of fibromyalgia comorbid with premenstrual dysphoric disorder with a low dose of venlafaxine.
100. Differences in free estradiol and sex hormone-binding globulin in women with and without premenstrual dysphoric disorder.
101. Patients with premenstrual dysphoric disorder have increased startle response across both cycle phases and lower levels of prepulse inhibition during the late luteal phase of the menstrual cycle.
102. Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder.
103. Duloxetine treatment of Premenstrual Dysphoric Disorder: case reports.
104. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
105. Ethinyl estradiol/drospirenone for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder.
106. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene.
107. Premenstrual dysphoric disorder--a neglected diagnosis? Preliminary study on a sample of Croatian students.
108. Premenstrual dysphoric disorder in an adolescent female.
109. A comparison of the Tridimensional Personality Questionnaire in premenstrual dysphoric disorder and major depressive disorder.
110. Premenstrual dysphoric disorder: treatment with sertraline, neuropsychological effects, and flight status.
111. Cyclical changes in calcium metabolism across the menstrual cycle in women with premenstrual dysphoric disorder.
112. Effectiveness of kamishoyosan for premenstrual dysphoric disorder: open-labeled pilot study.
113. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series.
114. Persistent alterations in biological profiles in women with abuse histories: influence of premenstrual dysphoric disorder.
115. Facial emotion discrimination across the menstrual cycle in women with premenstrual dysphoric disorder (PMDD) and controls.
116. Differentiation of women with premenstrual dysphoric disorder, recurrent brief depression, and healthy controls by daily mood rating dynamics.
117. Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder.
118. Premenstrual syndrome and premenstrual dysphoric disorder.
119. Premenstrual dysphoric disorder: prevalence, diagnostic considerations, and controversies.
120. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests.
121. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder.
122. Serotonin transporter, tryptophan hydroxylase, and monoamine oxidase A gene polymorphisms in premenstrual dysphoric disorder.
123. Premenstrual syndrome and premenstrual dysphoric disorder in adolescence.
124. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?
125. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese women.
126. Symptom-onset treatment for women with premenstrual dysphoric disorder.
127. [Premenstrual dysphoric disorder: diagnosis and therapeutic strategy].
128. Will oral contraceptives join SSRIs as a first-line treatment option for women with premenstrual dysphoric disorder?
129. Screening of patients for clinical trials of premenstrual syndrome/premenstrual dysphoric disorder: methodological issues.
130. Alexithymia and body image disturbances in women with Premenstrual Dysphoric Disorder.
131. Paroxetine use in the treatment of premenstrual dysphoric disorder.
132. Premenstrual dysphoric disorder in adolescents: case reports of treatment with fluoxetine and review of the literature.
133. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
134. Magnesium (mg) retention and mood effects after intravenous mg infusion in premenstrual dysphoric disorder.
135. Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder.
136. The effect of bright light therapy on depression associated with premenstrual dysphoric disorder.
137. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
138. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder.
139. Effectiveness of milnacipran for SSRI-intolerant patients with premenstrual dysphoric disorder.
140. Unexpected placebo response in premenstrual dysphoric disorder: implication of endogenous opioids.
141. Obstetrician-gynecologists' decision making about the diagnosis of major depressive disorder and premenstrual dysphoric disorder.
142. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder.
143. Histories of sexual abuse are associated with differential effects of clonidine on autonomic function in women with premenstrual dysphoric disorder.
144. Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder.
145. Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial.
146. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.
147. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder.
148. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder--clinical procedures and research perspectives.
149. Investigation of transcription factor AP-2 beta genotype in women with premenstrual dysphoric disorder.
150. Premenstrual dysphoric disorder. A clinical trial approach to assessment.
151. No correlation of depression and anxiety to plasma estrogen and progesterone levels in patients with premenstrual dysphoric disorder.
152. Lack of beneficial effects of clonidine in the treatment of premenstrual dysphoric disorder: results of a double-blind, randomized study.
153. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder.
154. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners.
155. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial.
156. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder.
157. Premenstrual syndrome, premenstrual dysphoric disorder, and premenstrual exacerbation of another disorder.
158. Withdrawal reactions associated with low-dose venlafaxine treatment in a patient with premenstrual dysphoric disorder.
159. Differential time course efficacy on dysphoric and physical symptoms of the intermittent dosing of fluoxetine in the premenstrual dysphoric disorder.
160. Historical sexual abuse and current thyroid axis profiles in women with premenstrual dysphoric disorder.
161. Premenstrual Dysphoric Disorder: Recognition and Treatment.
162. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.
163. Patient information. What is premenstrual dysphoric disorder (PMDD)?
164. Premenstrual dysphoric disorder: a review for the treating practitioner.
165. Altered sensitivity to alcohol in the late luteal phase among patients with premenstrual dysphoric disorder.
166. Heart rate variability in premenstrual dysphoric disorder.
167. St. John's wort (Hypericum perforatum) as a treatment for premenstrual dysphoric disorder: case report.
168. Premenstrual dysphoric disorder and changes in frontal alpha asymmetry.
169. Premenstrual dysphoric disorder and psychiatric co-morbidity.
170. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder.
171. Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder.
172. Attitudes toward menstruation in premenstrual dysphoric disorder: a preliminary report in an urban Turkish population.
173. Trauma and PTSD - an overlooked pathogenic pathway for premenstrual dysphoric disorder?
174. Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline.
175. Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes.
176. A biopsychosocial approach to premenstrual dysphoric disorder.
177. Treatment of premenstrual dysphoric disorder with selective serotonin reuptake inhibitors.
178. Biological correlates of abuse in women with premenstrual dysphoric disorder and healthy controls.
179. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder.
180. Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis.
181. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD).
182. Management of premenstrual dysphoric disorder.
183. How does premenstrual dysphoric disorder relate to depression and anxiety disorders?
184. Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine.
185. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder.
186. GABA receptors, progesterone and premenstrual dysphoric disorder.
187. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment.
188. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder.
189. [Premenstrual dysphoric disorder: approach and treatment].
190. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
191. Premenstrual dysphoric disorder: current status of treatment.
192. Clinical practice. Premenstrual dysphoric disorder.
193. [Assessment of premenstrual dysphoric disorder symptoms: population of women in Casablanca].
194. Distress levels in patients with premenstrual dysphoric disorder.
195. Myo-inositol has no beneficial effect on premenstrual dysphoric disorder.
196. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder.
197. Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder.
198. Pharmacotherapy of premenstrual syndromes and premenstrual dysphoric disorder: current practices.
199. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder.
200. Women with premenstrual dysphoric disorder do not recall aberrant parenting.
201. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder.
202. Premenstrual dysphoric disorder: is there an economic burden of illness?
203. Premenstrual dysphoric disorder. A protocol for management.
204. Information from your family doctor. Premenstrual dysphoric disorder (PMDD).
205. Diagnosis and treatment of premenstrual dysphoric disorder.
206. Pharmacological treatments for premenstrual dysphoric disorder.
207. Antidepressant-related hypomania in a patient with premenstrual dysphoric disorder.
208. SSRIs for premenstrual dysphoric disorder.
209. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries.
210. Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes.
211. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study.
212. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?
213. Herbal medicine (kami-shoyo-san) in the treatment of premenstrual dysphoric disorder.
214. Selective serotonin reuptake inhibitors and treatment of premenstrual dysphoric disorder.
215. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles.
216. Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder.
217. Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder.
218. Cognitive flexibility, reaction time, and attention in women with premenstrual dysphoric disorder.
219. Premenstrual dysphoric disorder. A guide for the treating clinician.
220. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
221. [Premenstrual dysphoric disorder. Recommendation for diagnosis of a distinct affective clinical picture].
222. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
223. Fluoxetine in the treatment of premenstrual dysphoric disorder.
224. Toward the content validity of premenstrual dysphoric disorder: do anger and irritability more than depressed mood represent treatment-seekers' experiences?
225. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community.
226. Role of family history and 5-HTTLPR polymorphism in female seasonal affective disorder patients with and without premenstrual dysphoric disorder.
227. Premenstrual syndrome and premenstrual dysphoric disorder.
228. Obstetrician-gynecologists' attitudes towards premenstrual dysphoric disorder and major depressive disorder.
229. Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard Study of Moods and Cycles.
230. Premenstrual dysphoric disorder and risk for major depressive disorder: a preliminary study.
231. Selections from current literature. Treatments for premenstrual dysphoric disorder.
232. Current management of premenstrual syndrome and premenstrual dysphoric disorder.
233. Venlafaxine in the treatment of premenstrual dysphoric disorder.
234. Treating premenstrual dysphoric disorder using serotonin agents.
235. Mood disorder history and personality assessment in premenstrual dysphoric disorder.
236. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
237. Premenstrual dysphoric disorder: a guide for patients and families.
238. Consumer & family information: premenstrual dysphoric disorder.
239. The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications.
240. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment.
241. Are women with premenstrual dysphoric disorder prone to osteoporosis?
242. Evaluation and management of premenstrual syndrome and premenstrual dysphoric disorder.
243. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder.
244. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder.
245. Porgesterone organogel for premenstrual dysphoric disorder.
246. Progesterone organogel for premenstrual dysphoric disorder.
247. Intermittent, luteal phase nefazodone treatment of premenstrual dysphoric disorder.
248. Medical management of premenstrual dysphoric disorder.
249. Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder.
250. Diagnosis and treatment of premenstrual dysphoric disorder: an update.
251. Fluoxetine (Sarafem) for premenstrual dysphoric disorder.
252. Physiological changes during carbon dioxide inhalation in patients with panic disorder, major depression, and premenstrual dysphoric disorder: evidence for a central fear mechanism.
253. Specificity of panic response to CO(2) inhalation in panic disorder: a comparison with major depression and premenstrual dysphoric disorder.
254. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management.
255. Premenstrual dysphoric disorder--a study from India.
256. Cortisol circadian rhythms during the menstrual cycle and with sleep deprivation in premenstrual dysphoric disorder and normal control subjects.
257. Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices.
258. History, evolution, and diagnosis of premenstrual dysphoric disorder.
259. Recognition of premenstrual dysphoric disorder and its treatment.
260. Relationships of premenstrual dysphoric disorder to major depression and anxiety disorders: a re-examination.
261. Clinical utility of the premenstrual assessment form as an instrument auxiliary to the diagnosis of premenstrual dysphoric disorder.
262. Is premenstrual dysphoric disorder a distinct clinical entity?
263. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives.
264. Progesterone organogel for premenstrual dysphoric disorder.
265. Response to flumazenil in women with premenstrual dysphoric disorder.
266. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo.
267. Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: is the fenfluramine challenge test still relevant?
268. [Sertraline in the treatment of premenstrual dysphoric disorder].
269. Citalopram increases pregnanolone sensitivity in patients with premenstrual dysphoric disorder.
270. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial.
271. A 45-year-old woman with premenstrual dysphoric disorder, 1 year later.
272. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study.
273. Mood, neuropsychological function and cognitions in premenstrual dysphoric disorder.
274. Bipolar II disorder vs. premenstrual dysphoric disorder.
275. Clinical crossroads: a 45-year-old woman with premenstrual dysphoric disorder.
276. The role of fluoxetine in the treatment of premenstrual dysphoric disorder.
277. Food "cravings" and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder.
278. Sleep EEG studies during early and late partial sleep deprivation in premenstrual dysphoric disorder and normal control subjects.
279. Symptom patterns of premenstrual dysphoric disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders-IV.
280. A 45-year-old woman with premenstrual dysphoric disorder.
281. Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases.
282. Dysregulation of cardiovascular and neuroendocrine responses to stress in premenstrual dysphoric disorder.
283. Mood disorders and the reproductive cycle: affective disorders during the menopause and premenstrual dysphoric disorder.
284. Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam.
285. Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet alpha 2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity.
286. Recurrent mood shifts of premenstrual dysphoric disorder can be mistaken for rapid-cycling bipolar II disorder.
287. Neuropsychological performance across the menstrual cycle in women with and without Premenstrual Dysphoric Disorder.
288. Adrenergic receptors in premenstrual dysphoric disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of luteal phase symptom severity.
289. Is sertraline an effective therapy for premenstrual dysphoric disorder?
290. Commonly asked questions about premenstrual dysphoric disorder.
291. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial.
292. Premenstrual dysphoric disorder and eating disorders.
293. Sertraline for premenstrual dysphoric disorder.
294. [Premenstrual dysphoric disorder: diagnostic and therapeutic approach].
295. [Premenstrual dysphoric disorder. An overview of diagnosis, epidemiology and therapeutic approaches].
296. Blunted phase-shift responses to morning bright light in premenstrual dysphoric disorder.
297. Premenstrual dysphoric disorder. What's that?
298. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group.
299. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder.
300. [Premenstrual dysphoric disorder: long-term treatment with fluoxetine and discontinuation].
301. Nefazodone- and/or sodium tetradecyl sulfate-associated leukopenia, fever, and shaking chills in a patient with premenstrual dysphoric disorder.
302. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder.
303. A design for studying the DSM-IV research criteria of premenstrual dysphoric disorder.
304. Plasma melatonin circadian rhythms during the menstrual cycle and after light therapy in premenstrual dysphoric disorder and normal control subjects.
305. Temperature circadian rhythms during the menstrual cycle and sleep deprivation in premenstrual dysphoric disorder and normal comparison subjects.
306. Psychobiology of premenstrual dysphoric disorder.
307. Establishing the diagnostic validity of premenstrual dysphoric disorder using rasch analysis.
308. The association between premenstrual dysphoric disorder and other mood disorders.
309. Antidepressants in the treatment of premenstrual dysphoric disorder.
310. Premenstrual dysphoric disorder. An update.
311. The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder.
312. Circadian rhythms of prolactin and thyroid-stimulating hormone during the menstrual cycle and early versus late sleep deprivation in premenstrual dysphoric disorder.
313. [Premenstrual dysphoric disorder: an epidemiological study].
314. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder.
315. Serotonin and premenstrual dysphoric disorder.
316. Paroxetine as a treatment for premenstrual dysphoric disorder.
317. Premenstrual dysphoric disorder: controversies surrounding the diagnosis.
318. Sertraline in the treatment of premenstrual dysphoric disorder.
319. Fluvoxamine for premenstrual dysphoric disorder: a pilot study.
320. Premenstrual syndrome no progesterone; premenstrual dysphoric disorder no serotonin deficiency.
321. Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide.
322. Early versus late partial sleep deprivation in patients with premenstrual dysphoric disorder and normal comparison subjects.
323. Premenstrual dysphoric disorder: evaluation, pathophysiology and treatment.